

The Future of Molecular Diagnostics

- Clinical and Business Cases
- Assessing and Advancing Molecular Diagnostic Technologies
- New Technologies & Innovative Companies



Session Format

- Brief presentation by each panelist
- 1-2 questions at end of each presentation
- Panel discussion follows completion of presentations for the panel
- Presentations will be posted on June 19 at www.rochesterbioventure.org
- Please turn off your cell phone or set it to vibrate during the presentations



Conference Agenda

- Conference overview
- Panel 1: Clinical and Business Cases (10:10am to 11:40am)
- Break & Lunch
- Panel 2: Assessing and Advancing Technologies (12:15 to 1:05pm)
- Break
- Panel 3: New Technologies and Innovative Companies (1:15pm to 2:30)
- End of formal sessions, stay as long as you like to speak with presenters and network with other attendees




The Future of Molecular Diagnostics

- Tests and methods to identify disease or predisposition to disease via DNA or RNA analysis
- Overlaps with In-Vitro Diagnostics
- Promise for earlier diagnosis, better outcomes
- Many factors impact adoption including:
 - Clinical needs and physician awareness,
 - Costs for tests/equipment/training,
 - Healthcare reimbursements,
 - Availability of approved devices and assays,
 - Patient acceptance, and a
 - Myriad of other issues



The Future of Molecular Diagnostics



©Jain PharmaBiotech

The Future of Molecular Diagnostics

Exchanging information among the many stakeholders that influence the adoption of molecular diagnostics is the key purpose for this conference

The topic is very broad and has many more aspects that we will not be able to address today

Desired outcomes from this event include:

- New insights into the potential for molecular diagnostics
- Formation of new collaborations
- On-going discussions concerning the future for innovation in devices, technologies and clinical applications developed in our region



The Future of Molecular Diagnostics

Clinical and Business Cases for Molecular Diagnostics

Robert Johnson – Program Administrator Pathology and Laboratory Medicine, University of Rochester Medical Center

Paul G. Rothberg, Ph.D. – Director of the Molecular Diagnostics Section of the Strong Health Clinical Laboratories

Bharat Kohli, MD, MBA—Chief Medical Officer, AHRM (Applied Healthcare and Resource Management)

Anne Marie Mullin—Vice President, Business Development and Marketing at the Laboratory Alliance of Central New York (LACNY)



The Future of Molecular Diagnostics

Assessing and Advancing Molecular Diagnostic Technologies

David Eilers – Vice President, Blue Highway LLC, a subsidiary of Welch Allyn

John Backus, Ph.D. – Group Director, Diagnostic Biomarker Evaluation,
Johnson & Johnson Ortho-Clinical Diagnostics



The Future of Molecular Diagnostics

New Technologies & Innovative Companies Addressing Molecular Diagnostics

Jeff Helfer—CEO, Diffinity Genomics

Jason Springs—Co-Founder & CEO, Geneweave BioSciences

Chris Strohsahl, Ph.D.—CTO, Lighthouse BioSciences, Inc.

Thomas Gaborski—COO and VP Life Sciences, SiMPore

Joel Grover – Co-Founder & President, Thermal Gradient

